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Prostate cancer (PCa) is the major cause of cancer-related death among the male population
of Western society, and androgen-deprivation therapy (ADT) represents the first line in PCa
treatment. However, although androgen receptor (AR) expression is maintained through-
out the various stages of PCa, ADT frequently fails. Clinical studies have demonstrated
that different androgen/AR signaling pathways operate in target tissues. AR stimulates
growth and transformation of target cells, but under certain conditions slows down their
proliferation. In this review, we discuss the role of AR in controlling different functions
of mesenchymal and transformed mesenchymal cells. Findings here presented support
the role of AR in suppressing proliferation and stimulating migration of stromal cells, with
implications for current approaches to cancer therapy.
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INTRODUCTION
Prostate cells are the primary targets of androgens, which regu-
late development, growth, and function of prostate. In this organ,
androgens act through the androgen receptor (AR), which is
expressed in both epithelium and stroma, and studies with recom-
binant tissues indicate that prostatic development is mediated by
stromal, but not epithelial AR (1). Sex steroids influence prostate
cancer (PCa) initiation and/or progression (2), whereas androgen
removal increases PCa cell death and inhibits cell proliferation.
Hence, androgen-deprivation therapy (ADT) is the standard ther-
apy for men with PCa. However, despite extensive efforts in the
clinical development of PCa therapies, current treatments only
control tumor growth initially, and fail to achieve long-term
efficacy since most PCa patients eventually relapse.
The role of epithelial AR in PCa has been extensively studied
in the last few decades. There are, however, many other AR target
tissues throughout the body (3), though specific information on
the role of AR in these cells is still minimal and few investigations
have been undertaken to elucidate the role of stromal AR. It has
been suggested that AR may direct stromal cells toward epithelial
PCa cells upon an increase in local androgen levels, as frequently
occurs in PCa (4). Stromal AR has also been shown to mediate
PCa metastasis (5) and induce prostatic intraepithelial neopla-
sia (6). Nonetheless, data on the role of stromal AR still remain
controversial.
AR paradoxically fosters or inhibits proliferation of target cells
depending on cell type, microenvironment, and hormone levels
(7). Reciprocal AR responses in epithelium and stroma regu-
late prostate development and homeostasis. Aberrant responses
might result in tumorigenesis. Androgen binding to AR induces
proliferation in PCa epithelial cells and differentiation in normal
prostate epithelial cells (8). Prostate stromal cells express AR, but
their growth is insensitive to androgen stimulation (9). Fibroblasts
and human fibrosarcoma HT1080 cells do not grow in response
to 10 nM androgen. At this hormone concentration, these cells
undergo migration as a consequence of a bipartite AR/filamin A
(FlnA) complex assembly (10, 11).
The dichotomous response (migration/proliferation) of
fibroblasts to different androgen concentrations mimics that of
growth factors, which trigger motility or proliferation [reviewed in
Ref. (12)]. A flurry of reports has investigated the molecular basis
for a cell decision to “go or grow.” EGF, VEGF, and PDGF trigger
motility or proliferation depending on cell type, receptor distribu-
tion or internalization, ligand concentration, and dynamic regula-
tion of signaling networks (13–17). In NIH3T3 cells, for instance,
low PDGF concentration induces migration, whereas high concen-
tration triggers proliferation. Cells make these different decisions
as a consequence of the different endocytic routes (clathrin- and
non-clathrin-mediated) engaged by the PDGF receptor (18). A
G-alpha i-GIV complex binds EGF-R and decides whether can-
cer cells migrate or proliferate (16). Again, interaction of the
EphB2 tyrosine kinase receptor with focal adhesion kinase (FAK)
promotes invasiveness and inhibits proliferation in glioblastoma
multiforme (19).
Here, we discuss the opposite (proliferative or migratory) func-
tions of stromal AR and the role of the upstream AR/FlnA complex
in stromal cell decision to “go or grow.” Since the AR/FlnA com-
plex drives androgen signaling toward migration and halts cell
cycle, this complex might be specifically targeted, with implica-
tions in the therapy of AR-related human diseases. The potential
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role of non-genomic signaling activated by androgen/AR axis in
cancer-associated fibroblasts (CAFs) is also discussed.
ANDROGEN SIGNALING IN STROMAL CELLS
AR mRNA levels are very similar in the stroma and epithelium,
although AR-mediated transcription is differentially regulated in
each, with a more active co-regulator recruitment by epithelial AR.
In the early 2000s, we made the exciting finding that NIH3T3
cells and mouse embryo fibroblasts (MEFs) harbor a transcrip-
tionally incompetent AR (20). Further expansion of the study led
to the discovery that AR plays a dual and opposite role in mes-
enchymal and transformed mesenchymal cells. At sub-optimal
androgen concentration (1 pM) AR mediates cell cycle progres-
sion and proliferation, while at optimal androgen concentration
(10 nM) the receptor halts mitogenesis and fosters migration (10,
11, 20). The dichotomous effect is not restricted to immortalized
(NIH3T3 cells) or transformed (HT1080 cells) fibroblasts, but can
also be observed in primary fibroblasts from adult or embryonic
mouse (11).
A few years ago, by recombination of prostate stromal WPMY-1
cells with PCa epithelial PC-3 cells in a mouse model, Niu and col-
leagues showed that stromal but not epithelial AR promotes tumor
proliferation at very early stage (21). Noteworthy, as occurs in
fibroblasts and transformed fibroblasts, prostate stromal WPMY-1
cells harbor a transcriptionally incompetent AR, which is perma-
nently localized in cytoplasm (22). Thus, the receptor expressed
in WPMY-1 cells likely promotes growth of epithelial PC-3 cells
through a non-transcriptional mechanism.
Prostate CAFs express AR, although the role of this receptor
in prostate tumorigenesis is still unclear. Loss of AR expression
in the tumor stroma, but not in the surrounding normal prostatic
stroma tissue, increases the risk of relapse following radical prosta-
tectomy (23, 24). Stromal AR expression progressively decreases
during PCa progression (22, 23). Thus, loss of stromal AR might
enable the growth,progression,and response to the therapy in PCa.
In apparent contrast with these findings, tissue-specific knockout
approach showed that deletion of AR in fibroblasts and fibro-
muscular cells (dARKO) inhibits the growth of PCa in mouse
model (6). A similar conclusion was reached using immortalized
CAFs from PCa biopsies (25). By using these experimental set-
tings, it has been shown that stromal AR modulates the release
of pro-inflammatory chemokines by CAFs, thereby promoting
recruitment of inflammatory and immune cells in tumor microen-
vironment (6, 25). These events may result in extracellular matrix
remodeling and angiogenesis, as well as proliferation and inva-
sion of neighboring epithelial PCa cells. In conclusion, conflicting
findings on the role of stromal AR can be obtained using differ-
ent experimental settings (i.e., tissue recombination in immune-
depressed mouse or AR tissue-specific knockout in immune-intact
mouse). Thus, further analysis of stromal AR should be under-
taken to gain valuable preclinical findings. Moreover, the contri-
bution of AR transcriptional and/or non-transcriptional activity
to biological responses in CAFs still remains elusive.
We have dissected in recent years the pathways activated by dif-
ferent androgen concentrations in fibroblasts, and this approach
has revealed some fascinating aspects. Low androgen concen-
tration (1 pM) induces proliferation in NIH3T3 fibroblasts as a
consequence of AR association with Src and p85, the regulatory
subunit of PI3-K (20). This complex activates MAPKs and Akt,
which then increase cyclin D1 expression and re-localize p27 to
cytoplasm for its subsequent degradation (11, 20). Conversely,
stimulation of NIH3T3 fibroblasts with optimal (nanomolar)
androgen concentration does not induce AR association with Src
and p85, but triggers AR association with the actin-binding pro-
tein, FlnA. Ten nM androgen stabilizes AR/FlnA co-localization at
intermediate cytoskeletal filaments and induces a complex includ-
ing AR/FlnA/integrin beta1 in NIH3T3 fibroblasts. This complex
triggers FAK and paxillin tyrosine phosphorylation. Furthermore,
the AR/FlnA/integrin beta1 complex activates Rac. These events
lead to cytoskeleton reorganization, adhesion changes, and cell
migration [(10); Figure 1].
On this basis, we may hypothesize that AR-mediated activation
of MAPK induces the release of chemokines and growth factors
by CAFs when androgen levels are low. Indeed, MAPK activation
increases growth factor release in various cancer cell types [(26)
and refs therein; (27)]. Again, by activating PI3-K at low androgen
concentration, stromal AR may act in concert with NF-kappa-
B to induce the release of macrophage inflammatory protein-1
beta (MIP-1beta) in tumor microenvironment, or it may activate
IKK-alpha-dependent gene transcription. Stromal AR co-operates
with NF-Kappa-B to modulate the gene expression of MIP-
1beta (6), and nuclear receptors induce IKK-alpha-dependent
epigenetic modifications and gene expression changes through
activation of PI3-K pathway (28, 29). When androgen levels
FIGURE 1 | Migratory pathway activated by androgens in
mesenchymal and transformed mesenchymal cells. Androgen (10 nM)
enhances AR/FlnA co-localization at intermediate cytoskeleton filaments
and induces a tripartite complex including AR/FlnA/integrin beta1 in NIH3T3
fibroblasts. This complex, likely through Trio-GEF, activates Rac. The
Fln-associated GTPase activating protein (Fil-GAP) might switch off Rac-GTP.
The AR/FlnA/integrin beta1 complex also triggers FAK and paxillin tyrosine
phosphorylation. Activation of this machinery modifies cytoskeleton actin
and cell adhesion, thus increasing motility of target cells (10).
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increase, CAFs might move toward epithelial PCa cells as a con-
sequence of the AR/FlnA complex assembly and activation of
molecular machinery involved in cell motility.
In conclusion, non-genomic functions of stromal AR might
either sustain the proliferation and invasiveness of epithelial PCa
cells or induce the recruitment of CAFs toward neighboring
epithelial PCa cells. Androgen levels in tumor microenvironment
may thus dictate the type of biological outcome in CAFs.
We recently showed that by increasing androgen concentration
from 1 pM to 10 nM, AR shifts from Src/PI3-K toward association
with FlnA, which in turns mediates the ligand-dependent activa-
tion of a different set of effectors (e.g., Trio-GEF, Rac) in stromal
cells. Thus, AR-protein interactions regulate the type of hormonal
responses, and these interactions are in turn controlled by ligand
concentration. Different androgen levels might, for instance, affect
post-translational modifications of AR. Phosphorylation, sumoy-
lation, acetylation, and ubiquitination are potential reversible
mechanisms affecting AR stability, localization, and interactions
of the receptor with other proteins [reviewed in Ref. (30, 31)]. By
enhancing the receptor interaction with signaling effectors, post-
translational modifications might impact the internalization route
of AR and receptor functions. In sum, there are different poten-
tial routes for androgens to orchestrate association of AR with
Src/PI3-K or FlnA, thus providing a mechanism for downstream
pathway regulation.
Migration rarely occurs in proliferating cells, and signals stim-
ulating migration inhibit cell proliferation [reviewed in Ref. (32)].
We recently identified androgen-activated Rac as the switch reg-
ulating transition from proliferative to migratory phenotype in
NIH3T3 fibroblasts and HT1080 fibrosarcoma cells. In these cells,
Rac activation by 10 nM androgen halts cell cycle progression
and triggers cell motility (11). Molecular studies have shown
that these cells make the decision to halt cell cycle by triggering
activation of the Rac-dependent DYRK 1B kinase upon chal-
lenging with 10 nM androgen. Once activated, DYRK 1B kinase
triggers Ser10 phosphorylation of p27 and its stabilization. This
pathway, which is controlled by the upstream AR/FlnA complex,
fosters cell quiescence, and even inhibits transformation induced
by oncogenic Ras [(11); Figure 2]. Thus, AR mediates growth sup-
pression by specifically targeting Ras-driven growth-promoting
pathways, highlighting the role of androgen/AR axis in human
cancers. Oncogenic Ras mutations have been described in car-
cinomas of the pancreas, colon, lung, and thyroid, as well as in
myeloid leukemia (33). Interestingly, most of these tumors (pan-
creas, colon, and lung) express AR (3, 34). Proliferation of various
pancreatic cancer-derived cells, which express AR, is insensitive to
androgens (35), and androgens inhibit survival signals in colon
cancer in vitro and in vivo (36). Again, small-cell lung carcinoma
H1184 cell line exhibits significant growth upon stimulation with
sub-optimal androgen concentrations, but is growth-inhibited
at higher androgen concentrations. Androgens also impair the
growth of non-small-cell lung carcinoma H1993 cell line (37).
Human fibrosarcoma HT1080 cells, exhibiting an activated N-
Ras, do not grow in response to high androgen concentrations (11,
34). Hence, the arguments put forward here raise the possibility
that androgens elicit anti-proliferative signals in human cancers
bearing oncogenic Ras mutations through activation of DYRK 1B.
Noteworthy, DYRK 1B is an active kinase in various human cancers
FIGURE 2 | Model of proliferative/migratory pathways activated by
androgens in mesenchymal and transformed mesenchymal cells. One
pM androgen triggers cell proliferation through the AR/Src/p85alpha complex
assembly (20). Ten nM androgen triggers the AR/FlnA complex assembly that
in turn activates Rac. Rac enhances cell migration (10) and triggers DYRK 1B
activation (11). This results in p27 Ser10 phosphorylation and p27 stabilization.
Quiescence of fibroblasts and human fibrosarcoma cells then follows (11). In
AR-expressing cells, oncogenic Ras or excessive growth factor stimuli
increase cyclin D1 expression and cell proliferation. By stimulating DYRK 1B
activation, 10 nM androgen triggers Ser10 phosphorylation and stabilization of
p27 (11). This event likely counteracts the effect of activated Ras or growth
factors on cyclin D1 and cell proliferation.
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and regulates Ras-driven transformation and tumor progression
(38–40). Thus, by activating DYRK 1B kinase, androgen/AR axis
might restrain Ras-driven transformation.
Stromal AR promotes the growth and differentiation of devel-
oping prostate, while it appears to inhibit the growth of PCa
under certain conditions (22). We recently observed that treat-
ment of androgen-stimulated mouse and MEFs, as well as NIH3T3
and HT1080 cells with the anti-androgen bicalutamide (Casodex)
increases cell proliferation. By displacing the androgen binding
to AR, bicalutamide inhibits AR-elicited migratory signals and
enables AR-mediated cell proliferation through the prevention
of AR/FlnA complex assembly (11). This finding is of interest,
since bicalutamide is frequently used in human PCa as ADT and
often promotes PCa progression [reviewed in Ref. (7)]. There-
fore, our recent results in migration/proliferation of mesenchy-
mal and transformed mesenchymal cells might partly clarify the
action of bicalutamide in enhancing PCa progression through
activation of undesired pathways in stromal cells. These data fur-
ther suggest that novel approaches are urgently needed for PCa
treatment.
In summary, our results show that upon 10 nM androgen-
triggered AR/FlnA complex assembly, FlnA acts as a scaffold for
Rac and effectors of its dependent pathway, thereby enabling
Rac activation and recruitment by Rac of specific signaling pro-
teins (e.g., DYRK 1B). These events lead to cell motility and
simultaneous cell cycle arrest in mesenchymal and transformed
mesenchymal cells. Interference in AR/FlnA complex assembly
by new molecules, such as AR-derived peptides (11), may rep-
resent a promising approach to the therapy of PCa by specifically
modulating signaling pathways activated by AR in stromal cells.
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